Who are we?
A Bold, Global Pharmaceutical Company
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry.
Our Company’s success is powered by our more than 17,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
Drugs Disributed by Allergan Israel Ltd
Bacterial Toxin. Botilium Toxin 50, 100, 200 U. PWDR. FOR INJECT: 50, 100, 200 U/vial. Spasm. torticollis: 25-300 units accord. to
individ. req. Intervals of at least 10-12
wks. strabismus: 1.25-5 units accord. to
pt. req. Blepharospasm: 1.25-5 units.
Axillary hyperhidros: Max. 50 U to each
axilla. See lit.
Spasmod. torticollis (cervic. diston.).,
strabis. and blepharospasm
dyston., benign essential blepharospasm,
nerve VII disords. in pts. over 12 yrs.,
dynamic equinus foot deform. due to
spastic. in ped. cerebral palsy, focal upper
limb spasticity associat. with stroke. Temp.
improve. appearance mod. to severe
glabellar lines assoc. with corrugator and/
or procerus muscle activity in adult pts. 65
yrs. or less. Manage. prim. axillary
hyperhidros. in pts. not respond. other
medical symptomat. tmt.
α2 Agonist, β Blocker. Brimonidine Tartrate 2 mg/ml, Timolol Maleate 5 mg/ml. OPHTH. SOLN: 5 ml. 1 drop in affect.
eye/s 2 x dly (± every 12 hrs.). If using
more than one top. ophth. soln, use 10
Chron. open-angle glaucoma, ocular
hypertens. not suffic. respond. to IOP
reduct. monother. or use not appropriate.
C/I: Hypersens., bronch. asth./history
thereof, severe chron. obstruct. pulm.
dis., sinus bradycard., 2nd/3rd degree
atrioventric block, overt card. fail.,
cardogen shock, MAOI ther.
Prostaglandin Analogues, β Blocker. Bimatoprost 0.3 mg/ml, Timolol Maleate 5 mg/ml. EYE DROPS: 3 ml. 1 drop in affect. eye/s
1 x dly in the morn.
Reduct. IOP in open angle glaucoma, occ.
hypertens. who are insuffic. respons. to
topic. beta-blockers or prostaglandin
C/I: Hypersens., react. airways dis., incl.
bronch. asthma or history, severe COPD,
sinus bradycard., 2nd/3rd degree AV
block, overt card. fail., cardiogen. shock.